Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant in COPD Patients With Eosinophilia
NCT03810183Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QAW039 450 mg with Placebo (2 arms). Primary endpoint: Change From Baseline in Sputum Eosinophil Percentage Based on Log-10 Transformed Scale at Week 6. Started May 2019; status: terminated.
02
Drugs
fevipiprant
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03810183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810183.